The prevalence of obesity is rapidly increasing worldwide. Obesity should not be understood only as the accumulation of fat in the body, but instead as a phenomenon that exerts different effects on our health according to the place of fat deposition and its stability. Obesity is the starting point of most metabolic diseases, such as diabetes, hypertension, metabolic syndrome, sleep apnea, and eventually cardiovascular disease. There are different kinds of obesity, ranging from simple obesity to sarcopenic obesity. The main purpose of intervening to address obesity is to decrease the ultimate consequence of obesity—namely, cardiovascular disease. The main mechanism through which obesity, especially abdominal obesity, increases cardiovascular risk is the obesity-induced derangement of metabolic health, leading to the development of metabolic diseases such as diabetes, non-alcoholic fatty liver disease, and metabolic syndrome, which are the main initiators of vascular damage. In this review, I discuss the influence of various types of obesity on the risk of metabolic diseases, and how these diseases increase cardiovascular disease risk.
Citations
Citations to this article as recorded by
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118. CrossRef
Severity of abdominal obesity and cardiometabolic diseases in US adults S. Wang, S. Shi, Y. Huang, H. Huang, V.W. Zhong Public Health.2024; 227: 154. CrossRef
Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study Caiyun Zhang, Xiaoping Dong, Jun Chen, Fang Liu Lipids in Health and Disease.2024;[Epub] CrossRef
Anti-obesity effects of fucoidan from
Sargassum thunbergii in adipocytes and high fat diet induced obese mice through inhibiting adipogenic specific transcription factor
Hyo-Geun Lee, H.H.A.C.K. Jayawardhana, Fengqi Yang, D.P. Nagahawaththa, N.M. Liyanage, Kyung-Mo Song, Yun-Sang Choi, Seung-Hong Lee, You-Jin Jeon, Min-Cheol Kang Food Science and Human Wellness.2024; 13(3): 1608. CrossRef
Association of a High Healthy Eating Index Diet with Long-Term Visceral Fat Loss in a Large Longitudinal Study Sunmin Park Nutrients.2024; 16(4): 534. CrossRef
Ancistrocladus tectorius Extract Inhibits Obesity by Promoting Thermogenesis and Mitochondrial Dynamics in High-Fat Diet-Fed Mice Minju Kim, Jin Hyub Paik, Hwa Lee, Min Ji Kim, Sang Mi Eum, Soo Yong Kim, Sangho Choi, Ho-Yong Park, Hye Gwang Jeong, Tae-Sook Jeong International Journal of Molecular Sciences.2024; 25(7): 3743. CrossRef
Biological Activity Evaluation of Olive, Grape, and Fig at Various Mixing Ratios Chan-Hwi Lee, So-Young Lee, Ae-Jung Kim Asian Journal of Beauty and Cosmetology.2024; 22(1): 91. CrossRef
Investigation and Comparison of Maternal Pre-Pregnancy Body Mass Index Coupled with Gestational Weight Gain on Maternal–Fetal Complications Based on US and Chinese Guidelines: A Retrospective Study Wan-Ju Kung, Hsin-Yi Kuo, Ching-Feng Chang, Yeong-Hwa Zen, Ching-Chiang Lin Reproductive Sciences.2024; 31(8): 2379. CrossRef
Docosahexanoic Acid Attenuates Palmitate-Induced Apoptosis by Autophagy Upregulation via GPR120/mTOR Axis in Insulin-Secreting Cells Seok-Woo Hong, Jinmi Lee, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee Endocrinology and Metabolism.2024; 39(2): 353. CrossRef
Adipokine Modulation in Endometrial Hyperplasia by Polyunsaturated Fatty Acids Athuru Supriya, Ammu V. V. V. Ravi Kiran, Praveen Thaggikuppe Krishnamurthy Journal of Pharmacology and Pharmacotherapeutics.2024; 15(3): 237. CrossRef
Association of osteoporosis with sarcopenia and its components among community-dwelling older Chinese adults with different obesity levels: A cross-sectional study Xing Yu, Yaqing Zheng, Yuewen Liu, Peipei Han, Xiaoyu Chen, Naiwen Zhang, Yejia Ni, Ziyi Zhou, Qi Guo Medicine.2024; 103(24): e38396. CrossRef
Association between mixed exposure to per- and polyfluoroalkyl substances and metabolic syndrome in Korean adults: Data from the Korean National environmental health survey cycle 4 Seung Min Chung, Kyun Hoo Kim, Jun Sung Moon, Kyu Chang Won International Journal of Hygiene and Environmental Health.2024; 261: 114427. CrossRef
Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide Chuxiong Zheng, Yumeng Li, Xin Wu, Le Gao, Xiaoyi Chen Nutrients.2024; 16(14): 2354. CrossRef
Impact of metabolic parameters and risk factors on surfactant proteins SP-A and SP-D in abdominal obesity K.Yu. Nikolaev, Ya.K. Lapitskaya, I.A. Kosarev, N.F. Dadashova Russian Journal of Preventive Medicine.2024; 27(7): 60. CrossRef
Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study Astrid Lavens, Christophe De Block, Philippe Oriot, Laurent Crenier, Jean-Christophe Philips, Michel Vandenbroucke, An-Sofie Vanherwegen, Frank Nobels, Chantal Mathieu Diabetologia.2024; 67(12): 2678. CrossRef
Association between lipid accumulation products and gallstones: an analysis of the National Health and Nutrition Examination Survey 2017–2020 Huimin Wang, Xiaojia Feng, Qihui Huang, Xiaowei Zheng BMC Gastroenterology.2024;[Epub] CrossRef
Lipid accumulation product, poverty income ratio, and bone mineral density in U.S. adults: a mediation analysis based on NHANES (2009–2020) Zihao Chen, Haobo Ye, Enli Li, Yuzhe Lin, Chen Jin, Lei Yang Frontiers in Nutrition.2024;[Epub] CrossRef
Epidemiology and Trends of Obesity and Bariatric Surgery in Korea Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim Endocrinology and Metabolism.2024; 39(5): 678. CrossRef
Assessment of Paraoxonase 1 and Arylesterase Activities and Lipid Profile in Bodybuilders: A Comparative Study of Physical Activity and Anthropometry on Atherosclerosis Hakim Celik, Mehmed Zahid Tuysuz, Yakup Aktas, Mehmet Ali Eren, Recep Demirbag Medicina.2024; 60(10): 1717. CrossRef
Evaluation of Health Associations With Height‐Normalised Abdominal Body Composition Indices: A Single‐Centre Cross‐Sectional Study Yupeng Liu, Hangqian He, Keyu Qian, Yufeng Huang, Xuemei Ao, Xudong Shi, Binye Ruan, Ru Xue, Xiaoyi Fu, Shuran Wang Journal of Cachexia, Sarcopenia and Muscle.2024;[Epub] CrossRef
Herbal appetite suppressants used to aid weight loss Sonia Malik, Sultana Patel, Dhvani H. Kuntawala, Gael N. N. Neba Ambe, Yannan Jin, Avninder S. Bhambra, Randolph R. J. Arroo Phytochemistry Reviews.2024;[Epub] CrossRef
Association between lipid accumulation products and stress urinary incontinence: a cross-sectional study from NHANES 2005 to 2018 JiHang Li, Dong Wang, Hu Tian, JianKun Yang, Hui Xia, WenBin Guo Lipids in Health and Disease.2024;[Epub] CrossRef
Impact of non-sugar sweeteners on metabolism beyond sweet taste perception Herbert Herzog, Lei Zhang, Luigi Fontana, G. Gregory Neely Trends in Endocrinology & Metabolism.2024;[Epub] CrossRef
Mechanistic insights into dietary (poly)phenols and vascular dysfunction-related diseases using multi-omics and integrative approaches: Machine learning as a next challenge in nutrition research Dragan Milenkovic, Tatjana Ruskovska Molecular Aspects of Medicine.2023; 89: 101101. CrossRef
Pharmacological Support for the Treatment of Obesity—Present and Future Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska, Tadeusz Pietras Healthcare.2023; 11(3): 433. CrossRef
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes Donna H. Ryan, John E. Deanfield, Stephan Jacob Cardiovascular Endocrinology & Metabolism.2023; 12(1): e0279. CrossRef
Adipopenia is associated with osteoporosis in community-dwelling non-underweight adults independent of sarcopenia Seunghyun Lee, Kyoungmyoung Ko, Sungjae Shin, Hye Sun Park, Namki Hong, Yumie Rhee Archives of Osteoporosis.2023;[Epub] CrossRef
Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism Shi-Yao Guo, Li-Yuan Wei, Bing-Bing Song, Yu-Tao Hu, Zhi Jiang, Dan-Dan Zhao, Yao-Hao Xu, Yu-Wei Lin, Shu-Min Xu, Shuo-Bin Chen, Zhi-Shu Huang European Journal of Medicinal Chemistry.2023; 260: 115729. CrossRef
Short-Term L-Citrulline Supplementation Does Not Affect Blood Pressure, Pulse Wave Reflection, or Arterial Stiffness at Rest and during Isometric Exercise in Older Males Andrea Tryfonos, Filippos Christodoulou, George M. Pamboris, Stephanos Christodoulides, Anastasios A. Theodorou Sports.2023; 11(9): 177. CrossRef
Skinfold Thickness as a Cardiometabolic Risk Predictor in Sedentary and Active Adult Populations Sughey González-Torres, Luis Miguel Anaya-Esparza, Gabriel Fermín Trigueros del Valle, Edgar Alfonso Rivera-León, Zuamí Villagrán, Sergio Sánchez-Enríquez Journal of Personalized Medicine.2023; 13(9): 1326. CrossRef
Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent Nutrients.2022; 14(14): 2795. CrossRef
Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo Frontiers in Nutrition.2022;[Epub] CrossRef
Predictive Roles of Basal Metabolic Rate and Body Water Distribution in Sarcopenia and Sarcopenic Obesity: The link to Carbohydrates Lizheng Guan, Tiantian Li, Xuan Wang, Kang Yu, Rong Xiao, Yuandi Xi Nutrients.2022; 14(19): 3911. CrossRef
Metabolic risk factors in patients with comorbidity in Ufa primary health care O.V. Molchanova, A.V. Mamaeva, A.R. Dunayeva, Z.A. Lust, E.M. Faskhetdinova, R.N. Shepel, D.O. Orlov, L.M. Zhamalov, G.F. Andreeva, O.M. Drapkina Profilakticheskaya meditsina.2022; 25(9): 39. CrossRef
Assessment of Vitamin D Levels in Relation to Statin Therapy in Elderly Hypertensive Patients with Comorbidities Kinga-Ilona Nyulas, Zsuzsánna Simon-Szabó, Zoltán Preg, Sándor Pál, Arundhati Sharma, Tünde Pál, Márta Germán-Salló, Enikő Nemes-Nagy Journal of Interdisciplinary Medicine.2022; 7(4): 88. CrossRef
Evidence for involvement of the central nervous system (CNS) in the regulation of glucose metabolism dates back to the 19th century, although the majority of the research on glucose metabolism has focused on the peripheral metabolic organs. Due to recent advances in neuroscience, it has now become clear that the CNS is indeed vital for maintaining glucose homeostasis. To achieve normoglycemia, specific populations of neurons and glia in the hypothalamus sense changes in the blood concentrations of glucose and of glucoregulatory hormones such as insulin, leptin, glucagon-like peptide 1, and glucagon. This information is integrated and transmitted to other areas of the brain where it eventually modulates various processes in glucose metabolism (i.e., hepatic glucose production, glucose uptake in the brown adipose tissue and skeletal muscle, pancreatic insulin and glucagon secretion, renal glucose reabsorption, etc.). Errors in these processes lead to hyper- or hypoglycemia. We here review the current understanding of the brain regulation of glucose metabolism.
Citations
Citations to this article as recorded by
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function Wenran Ren, Jianhui Chen, Wenjing Wang, Qingqing Li, Xia Yin, Guanglei Zhuang, Hong Zhou, Wenwen Zeng Neuron.2024; 112(6): 972. CrossRef
Hypothalamic astrocyte NAD+ salvage pathway mediates the coupling of dietary fat overconsumption in a mouse model of obesity Jae Woo Park, Se Eun Park, Wuhyun Koh, Won Hee Jang, Jong Han Choi, Eun Roh, Gil Myoung Kang, Seong Jun Kim, Hyo Sun Lim, Chae Beom Park, So Yeon Jeong, Sang Yun Moon, Chan Hee Lee, Sang Yeob Kim, Hyung Jin Choi, Se Hee Min, C. Justin Lee, Min-Seon Kim Nature Communications.2024;[Epub] CrossRef
Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells Praveen Sahu, Ignacio G. Camarillo, Raji Sundararajan Exploration of Targeted Anti-tumor Therapy.2024; 5(1): 54. CrossRef
Redox imbalance and metabolic defects in the context of Alzheimer disease Fabio Di Domenico, Chiara Lanzillotta, Marzia Perluigi FEBS Letters.2024;[Epub] CrossRef
Acid sphingomyelinase inhibition induces cerebral angiogenesis post-ischemia/reperfusion in an oxidative stress-dependent way and promotes endothelial survival by regulating mitochondrial metabolism Ayan Mohamud Yusuf, Mina Borbor, Tanja Hussner, Carolin Weghs, Britta Kaltwasser, Matthias Pillath-Eilers, Bernd Walkenfort, Richard Kolesnick, Erich Gulbins, Dirk M. Hermann, Ulf Brockmeier Cell Death & Disease.2024;[Epub] CrossRef
Antipsychotic-induced dysregulation of glucose metabolism through the central nervous system: a scoping review of animal models Emily Au, Kristoffer J. Panganiban, Sally Wu, Kira Sun, Bailey Humber, Gary Remington, Sri Mahavir Agarwal, Adria Giacca, Sandra Pereira, Margaret Hahn Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.2024;[Epub] CrossRef
Obesity-associated microglial inflammatory activation paradoxically improves glucose tolerance John D. Douglass, Kelly M. Ness, Martin Valdearcos, Alice Wyse-Jackson, Mauricio D. Dorfman, Jeremy M. Frey, Rachael D. Fasnacht, Olivia D. Santiago, Anzela Niraula, Jineta Banerjee, Megan Robblee, Suneil K. Koliwad, Joshua P. Thaler Cell Metabolism.2023; 35(9): 1613. CrossRef
Phenotypic screening using waveform analysis of synchronized calcium oscillations in primary cortical cultures Richi Sakaguchi, Saki Nakamura, Hiroyuki Iha, Masaki Tanaka, Ming Tatt Lee PLOS ONE.2023; 18(4): e0271782. CrossRef
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression Se Jong Oh, Namhun Lee, Kyung Rok Nam, Kyung Jun Kang, Sang Jin Han, Jae Yong Choi Molecular Imaging and Biology.2023; 25(4): 735. CrossRef
A Survey of Deep Learning for Alzheimer’s Disease Qinghua Zhou, Jiaji Wang, Xiang Yu, Shuihua Wang, Yudong Zhang Machine Learning and Knowledge Extraction.2023; 5(2): 611. CrossRef
Potassium channels in behavioral brain disorders. Molecular mechanisms and therapeutic potential: A narrative review Kazi Asraful Alam, Pernille Svalastoga, Aurora Martinez, Jeffrey Colm Glennon, Jan Haavik Neuroscience & Biobehavioral Reviews.2023; 152: 105301. CrossRef
Knockout of Nur77 Leads to Amino Acid, Lipid, and Glucose Metabolism Disorders in Zebrafish Yang Xu, Juanjuan Tian, Qi Kang, Hang Yuan, Chengdong Liu, Zhehui Li, Jie Liu, Mingyu Li Frontiers in Endocrinology.2022;[Epub] CrossRef
Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 2939. CrossRef
Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.
Citations
Citations to this article as recorded by
Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes Subo Dey, Jasmine Garg, Andy Wang, Eva Holzner, William H. Frishman, Wilbert S. Aronow Cardiology in Review.2024; 32(3): 285. CrossRef
Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents Tingting Zhang, Andrew R. Zullo, Kaleen (Kaley) N. Hayes, Dae Hyun Kim, Yoojin Lee, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry Journal of the American Medical Directors Association.2024; 25(3): 454. CrossRef
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park Diabetes Technology & Therapeutics.2024; 26(4): 222. CrossRef
Body composition and metabolic syndrome in patients with type 1 diabetes Qiong Zeng, Xiao-Jing Chen, Yi-Ting He, Ze-Ming Ma, Yi-Xi Wu, Kun Lin World Journal of Diabetes.2024; 15(1): 81. CrossRef
The best internal structure of the Diabetes Quality of Life Measure (DQOL) in Brazilian patients Denilson Menezes Almeida, Aldair Darlan Santos-de-Araújo, José Mário Costa Brito Júnior, Marcela Cacere, André Pontes-Silva, Cyrene Piazera Costa, Maria Cláudia Gonçalves, José Márcio Soares Leite, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai BMC Public Health.2024;[Epub] CrossRef
Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317. CrossRef
SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka Prospects in Pharmaceutical Sciences.2024; 22(1): 16. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim Diabetologia.2024; 67(7): 1235. CrossRef
Continuous glucose monitoring data for artificial intelligence-based predictive glycemic event: A potential aspect for diabetic care Lim Pei Ying, Oh Xin Yin, Ong Wei Quan, Neha Jain, Jayashree Mayuren, Manisha Pandey, Bapi Gorain, Mayuren Candasamy International Journal of Diabetes in Developing Countries.2024;[Epub] CrossRef
Optimizing postprandial glucose prediction through integration of diet and exercise: Leveraging transfer learning with imbalanced patient data Shinji Hotta, Mikko Kytö, Saila Koivusalo, Seppo Heinonen, Pekka Marttinen, Everson Nunes PLOS ONE.2024; 19(8): e0298506. CrossRef
Diet and gut microbiome: Impact of each factor and mutual interactions on prevention and treatment of type 1, type 2, and gestational diabetes mellitus Davide Menafra, Mattia Proganò, Nicola Tecce, Rosario Pivonello, Annamaria Colao Human Nutrition & Metabolism.2024; 38: 200286. CrossRef
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F. Pollock, Waqas Ahmed, Gregory J. Norman, Sang-Man Jin, Jae Hyeon Kim Journal of Medical Economics.2024; 27(1): 1245. CrossRef
Drug origami: A computation-guided approach for customizable drug release kinetics of oral formulations Hao Huang, Haoyu Zhang, Ningjie Du, Yidan Lyu, Jiahang Xu, Haoran Fu, Yixin Guan, Kewang Nan Matter.2024;[Epub] CrossRef
Bile acids, fibroblast growth factor-19, and glucagon-like peptide-1 levels in the long term after bariatric surgery Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song Asian Journal of Surgery.2024;[Epub] CrossRef
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures Kyoung Hwa Ha, Dae Jung Kim Endocrinology and Metabolism.2024; 39(5): 669. CrossRef
Utilisation of blood glucose test strips in insulin-requiring people with diabetes mellitus using continuous glucose monitoring in Saxony-Anhalt – Analysis of health insurance data Sara Lena Lückmann, Antonia Förster, Stephanie Heinrich, Christian Buhtz, Gabriele Meyer, Rafael Mikolajczyk, Steffen Fleischer Diabetes Research and Clinical Practice.2024; : 111935. CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus Ji Yoon Kim, Nam Hoon Kim Diabetes & Metabolism Journal.2023; 47(1): 42. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Cardiovascular Diabetology.2023;[Epub] CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko BMC Public Health.2023;[Epub] CrossRef
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef
Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study You Lee Yang, Eun-Ok Im, Yunmi Kim BMC Nursing.2023;[Epub] CrossRef
Access to novel anti-diabetic agents in resource limited settings: A brief commentary Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang World Journal of Diabetes.2023; 14(7): 939. CrossRef
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar Annals of Medicine.2023;[Epub] CrossRef
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya Expert Opinion on Pharmacotherapy.2023; 24(18): 2187. CrossRef
Analysis of the management and therapeutic performance of diabetes mellitus employing special target Hong-Yan Sun, Xiao-Yan Lin World Journal of Diabetes.2023; 14(12): 1721. CrossRef
Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Ana-Maria Pelin, Liliana Lacramioara Pavel, Ilie Cristian Drochioi, Gina Eosefina Botnariu Medicina.2022; 58(11): 1620. CrossRef
The Effectiveness of Eye Movement Desensitization and Reprocessing Therapy on Death Anxiety and Perceived Stress in Patients with Type 2 Diabetes Sh Valizadeh Shafagh, S Taklavi, R Kazemi Journal of Health and Care.2022; 24(3): 245. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.
Citations
Citations to this article as recorded by
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park BMJ.2024; : e076388. CrossRef
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective Inha Jung, Dae-Jeong Koo, Won-Young Lee Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289. CrossRef
Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki-Hyun Baek, Ki-Ho Song, Mee Kyoung Kim, Hyuk-Sang Kwon Diabetes Research and Clinical Practice.2022; 194: 110187. CrossRef
Cancer therapies targeting genetic alterations are a topic of great interest in the field of thyroid cancer, which frequently harbors mutations in the RAS, RAF, and RET genes. Unfortunately, U.S. Food and Drug Administration-approved BRAF inhibitors have relatively low therapeutic efficacy against BRAF-mutant thyroid cancer; in addition, the cancer often acquires drug resistance, which prevents effective treatment. Recent advances in genomics and transcriptomics are leading to a more complete picture of the range of mutations, both driver and messenger, present in thyroid cancer. Furthermore, our understanding of cancer suggests that oncogenic mutations drive tumorigenesis and induce rewiring of cancer cell metabolism, which promotes survival of mutated cells. Synthetic lethality (SL) is a method of neutralizing mutated genes that were previously considered untargetable by traditional genotype-targeted treatments. Because these metabolic events are specific to cancer cells, we have the opportunity to develop new therapies that target tumor cells specifically without affecting healthy tissue. Here, we describe developments in metabolism-based cancer therapy, focusing on the concept of metabolic SL in thyroid cancer. Finally, we discuss the essential implications of metabolic reprogramming and its role in the future direction of SL for thyroid cancer.
Citations
Citations to this article as recorded by
Emerging Strategies for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Combining Immune Checkpoint Inhibitors with VEGF Inhibitors Young Joo Park Clinical Thyroidology®.2024; 36(10): 377. CrossRef
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park Endocrinology and Metabolism.2023; 38(6): 619. CrossRef
The Role of De novo Serine Biosynthesis from Glucose in Papillary Thyroid Cancer Seong Eun Lee, Na Rae Choi, Jin-Man Kim, Mi Ae Lim, Bon Seok Koo, Yea Eun Kang International Journal of Thyroidology.2023; 16(2): 175. CrossRef
Background Most studies of systematic drug repositioning have used drug-oriented data such as chemical structures, gene expression patterns, and adverse effect profiles. As it is often difficult to prove repositioning candidates’ effectiveness in real-world clinical settings, we used patient-centered real-world data for screening repositioning candidate drugs for multiple diseases simultaneously, especially for diabetic complications.
Methods Using the National Health Insurance Service-National Sample Cohort (2002 to 2013), we analyzed claims data of 43,048 patients with type 2 diabetes mellitus (age ≥40 years). To find repositioning candidate disease-drug pairs, a nested case-control study was used for 29 pairs of diabetic complications and the drugs that met our criteria. To validate this study design, we conducted an external validation for a selected candidate pair using electronic health records.
Results We found 24 repositioning candidate disease-drug pairs. In the external validation study for the candidate pair cerebral infarction and glycopyrrolate, we found that glycopyrrolate was associated with decreased risk of cerebral infarction (hazard ratio, 0.10; 95% confidence interval, 0.02 to 0.44).
Conclusion To reduce risks of diabetic complications, it would be possible to consider these candidate drugs instead of other drugs, given the same indications. Moreover, this methodology could be applied to diseases other than diabetes to discover their repositioning candidates, thereby offering a new approach to drug repositioning.
Citations
Citations to this article as recorded by
Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease Jae-Bong Kim, Yujeong Kim, Soo-Jeong Kim, Tae‑Young Ha, Dong-Kyu Kim, Dong Won Kim, Minyoung So, Seung Ho Kim, Hyun Goo Woo, Dukyong Yoon, Sang Myun Park Journal of Neuroinflammation.2024;[Epub] CrossRef
Drug Repositioning: Exploring New Indications for Existing Drug-Disease Relationships Hun-Sung Kim Endocrinology and Metabolism.2022; 37(1): 62. CrossRef
Background Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to reduce body weight and liver fat content in patients with type 2 diabetes. Family with sequence similarity 3 member A (FAM3A) plays a vital role in regulating glucose and lipid metabolism. The aim of this study was to determine the mechanisms by which dulaglutide protects against hepatic steatosis in HepG2 cells treated with palmitic acid (PA).
Methods HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM dulaglutide for 24 hours. Hepatic lipid accumulation was determined using Oil red O staining and triglyceride (TG) assay, and the expression of lipid metabolism-associated factor was analyzed using quantitative real time polymerase chain reaction and Western blotting.
Results Dulaglutide significantly decreased hepatic lipid accumulation and reduced the expression of genes associated with lipid droplet binding proteins, de novo lipogenesis, and TG synthesis in PA-treated HepG2 cells. Dulaglutide also increased the expression of proteins associated with lipolysis and fatty acid oxidation and FAM3A in PA-treated cells. However, exendin-(9-39), a GLP-1R antagonist, reversed the expression of FAM3A, and fatty acid oxidation-associated factors increased due to dulaglutide. In addition, inhibition of FAM3A by siRNA attenuated the reducing effect of dulaglutide on TG content and its increasing effect on regulation of fatty acid oxidation.
Conclusion These results suggest that dulaglutide could be used therapeutically for improving nonalcoholic fatty liver disease, and its effect could be mediated in part via upregulation of FAM3A expression through a GLP-1R-dependent pathway.
Citations
Citations to this article as recorded by
GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD Haoran Jiang, Linquan Zang Current Pharmaceutical Design.2024; 30(2): 100. CrossRef
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan Diabetes & Metabolism Journal.2024; 48(3): 354. CrossRef
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective Inha Jung, Dae-Jeong Koo, Won-Young Lee Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano Frontiers in Endocrinology.2024;[Epub] CrossRef
Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study Toshitaka Sawamura, Ren Mizoguchi, Ai Ohmori, Mitsuhiro Kometani, Takashi Yoneda, Shigehiro Karashima Journal of Diabetes & Metabolic Disorders.2024;[Epub] CrossRef
FABP1 induces lipogenesis by regulating the processing of SREBP1 in hepatocytes of large yellow croaker (Larimichthys crocea) Fan Chen, Tingting Hao, Qiang Chen, Yuning Sun, Yanan Shen, Zengqi Zhao, Jianlong Du, Yueru Li, Kangsen Mai, Qinghui Ai The FASEB Journal.2024;[Epub] CrossRef
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso International Journal of Molecular Sciences.2023; 24(2): 1703. CrossRef
FAM3A mediates the phenotypic switch of human aortic smooth muscle cells stimulated with oxidised low-density lipoprotein by influencing the PI3K-AKT pathway Lei Yang, Baoshun Du, Shitao Zhang, Maode Wang In Vitro Cellular & Developmental Biology - Animal.2023; 59(6): 431. CrossRef
ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism Jing Li, Han Yan, Rui Xiang, Weili Yang, Jingjing Ye, Ruili Yin, Jichun Yang, Yujing Chi Frontiers in Physiology.2022;[Epub] CrossRef
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Background Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear.
Methods In order to elucidate risk factors for ICI-T1DM, we evaluated the clinical course and immunological status of patients with ICI-T1DM who had been diagnosed during 2016 to 2021.
Results Seven of 871 (0.8%, six men and one woman) patients developed ICI-T1DM. We revealed that the allele frequencies of human leukocyte antigen (HLA)-DPA1*02:02 and DPB1*05:01 were significantly higher in the patients with ICI-T1DM In comparison to the controls who received ICI (11/14 vs. 10/26, P=0.022; 11/14 vs. 7/26, P=0.0027, respectively). HLA-DRB1*04:05, which has been found to be a T1DM susceptibility allele in Asians, was also observed as a high-risk allele for ICI-T1DM. The significance of the HLA-DPB1*05:01 and DRB1*04:05 alleles was confirmed by an analysis of four additional patients. The absolute/relative neutrophil count, neutrophils-lymphocyte ratio, and neutrophil-eosinophil ratio increased, and the absolute lymphocyte count and absolute/relative eosinophil count decreased at the onset as compared with 6 weeks before. In two patients, alterations in cytokines and chemokines were found at the onset.
Conclusion Novel high-risk HLA alleles and haplotypes were identified in ICI-T1DM, and peripheral blood factors may be utilized as biomarkers.
Citations
Citations to this article as recorded by
Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa Diabetology International.2024; 15(1): 130. CrossRef
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen Cancer Treatment Reviews.2024; 122: 102662. CrossRef
Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes Shunya Yabuki, Hiroyuki Hirai, Chihiro Moriya, Yoshiro Kusano, Takeo Hasegawa Frontiers in Endocrinology.2024;[Epub] CrossRef
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria Anna Angelousi, Dimitrios C. Ziogas, Vasiliki Siampanopoulou, Chrysoula Mytareli, Amalia Anastasopoulou, George Lyrarakis, Helen Gogas Diseases.2024; 12(2): 40. CrossRef
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal Cancers.2024; 16(6): 1225. CrossRef
A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano Diabetology International.2024; 15(3): 583. CrossRef
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis Mayo Ono, Mototsugu Nagao, Haruki Takeuchi, Etsuya Fukunaga, Tomoko Nagamine, Kyoko Inagaki, Izumi Fukuda, Masato Iwabu European Journal of Endocrinology.2024; 191(1): 9. CrossRef
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A. Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A. Paschou Endocrine.2024;[Epub] CrossRef
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome John Marsiglio, Jordan P. McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P. Soares, Katie Kerrigan, Berit Gibson, Jennifer Anne Doherty, John Hyngstrom, Sheetal Frontiers in Immunology.2023;[Epub] CrossRef
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis Cancers.2023; 15(2): 375. CrossRef
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors Cancers.2023; 15(5): 1629. CrossRef
Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors Hidefumi Inaba, Shuhei Morita, Daisuke Kosugi, Yuki Asai, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Masao Ota, Yuko Okudaira, Hiroyasu Nakatani, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, T Frontiers in Immunology.2023;[Epub] CrossRef
Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study Natsuko Hara, Hirotsugu Suwanai, Fumiyoshi Yakou, Keitaro Ishii, Hajime Iwasaki, Hironori Abe, Jumpei Shikuma, Hiroyuki Sakai, Takashi Miwa, Ryo Suzuki Endocrine.2023; 81(3): 477. CrossRef
Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis Fiamma Berner, Lukas Flatz Immunological Reviews.2023; 318(1): 37. CrossRef
Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland Ichiro Yamauchi, Takuro Hakata, Taku Sugawa, Daisuke Kosugi, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Norio Harada, Nobuya Inagaki Endocrine Journal.2023; 70(10): 987. CrossRef
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs Yihan Zhou, Shan Ding Cancers.2023; 15(23): 5622. CrossRef
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A. Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen Expert Review of Anticancer Therapy.2022; 22(8): 861. CrossRef
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne Frontiers in Immunology.2022;[Epub] CrossRef
Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice Pablo Rodríguez de Vera-Gómez, Ana Piñar-Gutiérrez, Raquel Guerrero-Vázquez, Virginia Bellido, Cristóbal Morales-Portillo, María Pilar Sancho-Márquez, Pablo Espejo-García, Noelia Gros-Herguido, Gema López-Gallardo, María Asunción Martínez-Brocca, Alfonso Journal of Diabetes Research.2022; 2022: 1. CrossRef
Kyung Bong Ha, Weerapon Sangartit, Ah Reum Jeong, Eun Soo Lee, Hong Min Kim, Soyeon Shim, Upa Kukongviriyapan, Dae-Kee Kim, Eun Young Lee, Choon Hee Chung
Endocrinol Metab. 2022;37(1):96-111. Published online February 28, 2022
Background Diabetic nephropathy (DN) is characterized by albuminuria and accumulation of extracellular matrix (ECM) in kidney. Transforming growth factor-β (TGF-β) plays a central role in promoting ECM accumulation. We aimed to examine the effects of EW-7197, an inhibitor of TGF-β type 1 receptor kinase (ALK5), in retarding the progression of DN, both in vivo, using a diabetic mouse model (db/db mice), and in vitro, in podocytes and mesangial cells.
Methods In vivo study: 8-week-old db/db mice were orally administered EW-7197 at a dose of 5 or 20 mg/kg/day for 10 weeks. Metabolic parameters and renal function were monitored. Glomerular histomorphology and renal protein expression were evaluated by histochemical staining and Western blot analyses, respectively. In vitro study: DN was induced by high glucose (30 mM) in podocytes and TGF-β (2 ng/mL) in mesangial cells. Cells were treated with EW-7197 (500 nM) for 24 hours and the mechanism associated with the attenuation of DN was investigated.
Results Enhanced albuminuria and glomerular morphohistological changes were observed in db/db compared to that of the nondiabetic (db/m) mice. These alterations were associated with the activation of the TGF-β signaling pathway. Treatment with EW-7197 significantly inhibited TGF-β signaling, inflammation, apoptosis, reactive oxygen species, and endoplasmic reticulum stress in diabetic mice and renal cells.
Conclusion EW-7197 exhibits renoprotective effect in DN. EW-7197 alleviates renal fibrosis and inflammation in diabetes by inhibiting downstream TGF-β signaling, thereby retarding the progression of DN. Our study supports EW-7197 as a therapeutically beneficial compound to treat DN.
Citations
Citations to this article as recorded by
TGF-β signaling in health, disease and therapeutics Ziqin Deng, Tao Fan, Chu Xiao, He Tian, Yujia Zheng, Chunxiang Li, Jie He Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Endoplasmic Reticulum Stress-Mediated Cell Death in Renal Fibrosis Shangze Guo, Yinghao Tong, Ting Li, Kexin Yang, Wei Gao, Fujun Peng, Xiangyu Zou Biomolecules.2024; 14(8): 919. CrossRef
Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols Qi Jin, Tongtong Liu, Yuan Qiao, Donghai Liu, Liping Yang, Huimin Mao, Fang Ma, Yuyang Wang, Liang Peng, Yongli Zhan Frontiers in Immunology.2023;[Epub] CrossRef
Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis Kyung Bong Ha, Eun Soo Lee, Na Won Park, Su Ho Jo, Soyeon Shim, Dae-Kee Kim, Chan Mug Ahn, Choon Hee Chung Diabetes & Metabolism Journal.2023; 47(4): 500. CrossRef
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background There are differences in risk and risk factor findings of postpartum type 2 diabetes mellitus (T2DM) after gestational diabetes depending on study design and subjects of previous studies. This study aimed to assess these risk and risk factors more accurately through a population-based study to provide basic data for prevention strategies.
Methods This open retrospective cohort included data of 419,101 women with gestational diabetes and matched 1,228,802 control women who delivered between 2004 and 2016 from the South Korea National Health Information Database of the National Health Insurance Service. Following 14 (median 5.9) years of follow-up, the incidence and hazard ratio (HR) of postpartum T2DM were evaluated using Kaplan-Meier curves and Cox proportional regression models.
Results The incidence and HR of postpartum T2DM in women with gestational diabetes (compared to women without gestational diabetes) after the 14-year follow-up was 21.3% and 2.78 (95% confidence interval [CI], 2.74 to 2.82), respectively. Comorbid obesity (body mass index [BMI] ≥25 kg/m2) increased postpartum T2DM risk 7.59 times (95% CI, 7.33 to 7.86). Significant risk factors for postpartum T2DM were fasting glucose level, BMI, age, family history of diabetes, hypertension, and insulin use during pregnancy.
Conclusion This population-based study showed higher postpartum T2DM risk in women with gestational diabetes than in those without, which was further increased by comorbid obesity. BMI and fasting glucose level were important postpartum risk factors. The management of obesity and glycemic control may be important strategies to prevent the incidence of diabetes after delivery.
Citations
Citations to this article as recorded by
Antenatal factors and risk of postpartum hyperglycemia in women with gestational diabetes mellitus: A central India prospective cohort study Nilajkumar Bagde, Madhuri Bagde, Vijayalakshmi Shanbhag, Pragati Trigunait, Nagma Sheikh, Sarita Agrawal Journal of Family Medicine and Primary Care.2024; 13(1): 59. CrossRef
Changes in the Epidemiological Landscape of Diabetes in South Korea: Trends in Prevalence, Incidence, and Healthcare Expenditures Kyoung Hwa Ha, Dae Jung Kim Endocrinology and Metabolism.2024; 39(5): 669. CrossRef
Integration of nutrigenomics, melatonin, serotonin and inflammatory cytokines in the pathophysiology of pregnancy-specific urinary incontinence in women with gestational diabetes mellitus Danielle Cristina Honorio França, Eduardo Luzía França, Luis Sobrevia, Angélica Mércia Pascon Barbosa, Adenilda Cristina Honorio-França, Marilza Vieira Cunha Rudge Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2023; 1869(6): 166737. CrossRef
Risk factors associated with early postpartum glucose intolerance in women with a history of gestational diabetes mellitus: a systematic review and meta-analysis Zhe Liu, Qianghuizi Zhang, Leyang Liu, Weiwei Liu Endocrine.2023; 82(3): 498. CrossRef
Background Monitoring adults with classical 21-hydroxylase deficiency (21OHD) is challenging due to variation in clinical and laboratory settings. Moreover, guidelines for adrenal imaging in 21OHD are not yet available. We evaluated the relationship between adrenal morphology and disease control status in classical 21OHD.
Methods This retrospective, cross-sectional study included 90 adult 21OHD patients and 270 age- and sex-matched healthy controls. We assessed adrenal volume, width, and tumor presence using abdominal computed tomography and evaluated correlations of adrenal volume and width with hormonal status. We investigated the diagnostic performance of adrenal volume and width for identifying well-controlled status in 21OHD patients (17α-hydroxyprogesterone [17-OHP] <10 ng/mL).
Results The adrenal morphology of 21OHD patients showed hypertrophy (45.6%), normal size (42.2%), and hypotrophy (12.2%). Adrenal tumors were detected in 12 patients (13.3%). The adrenal volume and width of 21OHD patients were significantly larger than those of controls (18.2±12.2 mL vs. 7.1±2.0 mL, 4.7±1.9 mm vs. 3.3±0.5 mm, P<0.001 for both). The 17-OHP and androstenedione levels were highest in patients with adrenal hypertrophy, followed by those with normal adrenal glands and adrenal hypotrophy (P<0.05 for both). Adrenal volume and width correlated positively with adrenocorticotropic hormone, 17-OHP, 11β-hydroxytestosterone, progesterone sulfate, and dehydroepiandrosterone sulfate in both sexes (r=0.33–0.95, P<0.05 for all). For identifying well-controlled patients, the optimal cut-off values of adrenal volume and width were 10.7 mL and 4 mm, respectively (area under the curve, 0.82–0.88; P<0.001 for both).
Conclusion Adrenal volume and width may be reliable quantitative parameters for monitoring patients with classical 21OHD.
Citations
Citations to this article as recorded by
Long‐term health consequences of congenital adrenal hyperplasia Riccardo Pofi, Xiaochen Ji, Nils P. Krone, Jeremy W. Tomlinson Clinical Endocrinology.2024; 101(4): 318. CrossRef
Landscape of Adrenal Tumours in Patients with Congenital Adrenal Hyperplasia Mara Carsote, Ana-Maria Gheorghe, Claudiu Nistor, Alexandra-Ioana Trandafir, Oana-Claudia Sima, Anca-Pati Cucu, Adrian Ciuche, Eugenia Petrova, Adina Ghemigian Biomedicines.2023; 11(11): 3081. CrossRef
Multiplexed Serum Steroid Profiling Reveals Metabolic Signatures of Subtypes in Congenital Adrenal Hyperplasia Jaeyoon Shim, Chang Ho Ahn, Seung Shin Park, Jongsung Noh, Chaelin Lee, Sang Won Lee, Jung Hee Kim, Man Ho Choi Journal of the Endocrine Society.2023;[Epub] CrossRef
Long-Term Outcomes of Congenital Adrenal Hyperplasia Anna Nordenström, Svetlana Lajic, Henrik Falhammar Endocrinology and Metabolism.2022; 37(4): 587. CrossRef
Congenital adrenal hyperplasia in patients with adrenal tumors: a population-based case–control study F. Sahlander, J. Patrova, B. Mannheimer, J. D. Lindh, H. Falhammar Journal of Endocrinological Investigation.2022; 46(3): 559. CrossRef
Fully automatic volume measurement of the adrenal gland on CT using deep learning to classify adrenal hyperplasia Taek Min Kim, Seung Jae Choi, Ji Yeon Ko, Sungwan Kim, Chang Wook Jeong, Jeong Yeon Cho, Sang Youn Kim, Young-Gon Kim European Radiology.2022; 33(6): 4292. CrossRef
Adrenal Gland Big Data Articles (National Health Insurance Service Database)
Background Previous studies on the epidemiology and complications of congenital adrenal hyperplasia (CAH) were conducted in Western countries and in children/adolescents. We aimed to explore the epidemiology of CAH, as well as the risk of comorbidities and mortality, in a Korean nationwide case-control study.
Methods CAH patients (n=2,840) were included between 2002 and 2017 from the National Health Insurance Service database and the Rare Intractable Disease program. CAH patients were compared, at a 1:10 ratio, with age-, sex-, and index year-matched controls (n=28,400).
Results The point prevalence of CAH patients in Korea was 1 in 18,745 persons in 2017. The annual incidence rate declined between 2003 and 2017 from 3.25 to 0.41 per 100,000 persons. CAH patients were at elevated risk for cardiovascular disease (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.4 to 1.9), stroke (OR, 1.7; 95% CI, 1.3 to 2.0), diabetes mellitus (OR, 2.8; 95% CI, 2.6 to 3.1), dyslipidemia (OR, 2.4; 95% CI, 2.2 to 2.6), and psychiatric disorders (OR, 1.5; 95% CI, 1.3 to 1.6). Fracture risk increased in CAH patients aged over 40 years (OR, 1.4; 95% CI, 1.1 to 1.7). CAH patients were at higher risk of mortality than controls (hazard ratio, 1.6; 95% CI, 1.3 to 2.0).
Conclusion Our nationwide study showed a recent decline in the incidence of CAH and an elevated risk for cardiovascular, metabolic, skeletal, and psychiatric disorders in CAH patients. Lifelong management for comorbidity risk is a crucial component of treating CAH patients.
Citations
Citations to this article as recorded by
Long‐term health consequences of congenital adrenal hyperplasia Riccardo Pofi, Xiaochen Ji, Nils P. Krone, Jeremy W. Tomlinson Clinical Endocrinology.2024; 101(4): 318. CrossRef
Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence? Angelica Lindén Hirschberg The Journal of Clinical Endocrinology & Metabolism.2024; 109(5): 1202. CrossRef
Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia Suranut Charoensri, Richard J Auchus The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1133. CrossRef
Case report: Development of central precocious puberty in a girl with late-diagnosed simple virilizing congenital adrenal hyperplasia complicated with Williams syndrome Eun Young Joo, Myung Ji Yoo, Su Jin Kim, Woori Jang, Ji-Eun Lee Frontiers in Endocrinology.2024;[Epub] CrossRef
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia Robert Krysiak, Hedi L Claahsen-van der Grinten, Nicole Reisch, Philippe Touraine, Henrik Falhammar Endocrine Reviews.2024;[Epub] CrossRef
Proof of concept for a superior therapeutic index of corticosterone compared with hydrocortisone in patients with congenital adrenal hyperplasia Catriona J Kyle, Luke D Boyle, Mark Nixon, Natalie Z M Homer, Joanna P Simpson, Alison Rutter, Lynne E Ramage, Alexandra Kelman, Ellen Marie Freel, Ruth Andrew, Brian R Walker, Roland H Stimson European Journal of Endocrinology.2024; 191(6): 535. CrossRef
Анализ распространенности и заболеваемости надпочечниковой недостаточностью в мире М. Ю. Юкина, Н. Ф. Нуралиева, Е. А. Трошина Ateroscleroz.2023; 18(4): 426. CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia Beatrice Righi, Salma R. Ali, Jillian Bryce, Jeremy W. Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C. Costa, Guilherme Guaragna-Filho, Guy T’Sjoen, Martine Cools, Renata Markosyan, Tania A. S. S. Bachega, Mirela C. Miranda, Violeta Iotova, Henrik Endocrine.2023; 80(3): 630. CrossRef
Serum steroid profile captures metabolic phenotypes in adults with classic congenital adrenal hyperplasia Chang Ho Ahn, Jaeyoon Shim, Han Na Jang, Young Ah Lee, Sang-Won Lee, Man Ho Choi, Jung Hee Kim The Journal of Steroid Biochemistry and Molecular Biology.2023; 234: 106374. CrossRef
Multiplexed Serum Steroid Profiling Reveals Metabolic Signatures of Subtypes in Congenital Adrenal Hyperplasia Jaeyoon Shim, Chang Ho Ahn, Seung Shin Park, Jongsung Noh, Chaelin Lee, Sang Won Lee, Jung Hee Kim, Man Ho Choi Journal of the Endocrine Society.2023;[Epub] CrossRef
Long-Term Outcomes of Congenital Adrenal Hyperplasia Anna Nordenström, Svetlana Lajic, Henrik Falhammar Endocrinology and Metabolism.2022; 37(4): 587. CrossRef
Calcium & Bone Metabolism Big Data Articles (National Health Insurance Service Database)
Background Diabetic kidney disease (DKD) is associated with an elevated risk of fractures. However, little is known about the association between proteinuric or non-proteinuric DKD and the risk of hip fracture. Thus, we investigated the incidence of hip fractures among Korean adults with type 2 diabetes mellitus (T2DM) stratified by DKD phenotype.
Methods In this retrospective cohort study using the Korean National Health Insurance Service database, patients with T2DM who received at least one general health checkup between 2009 and 2012 were followed until the date of hip fracture, death, or December 31, 2018. We classified the DKD phenotype by proteinuria and estimated glomerular filtration rate (eGFR), as follows: no DKD (PU−GFR−), proteinuric DKD with normal eGFR (PU+GFR−), non-proteinuric DKD with reduced eGFR (PU−GFR+), and proteinuric DKD with reduced eGFR (PU+GFR+)
Results The cumulative incidence of hip fractures was highest in the PU+GFR+ group, followed by the PU−GFR+ group and the PU+GFR− group. After adjustment for confounding factors, the hazard ratio (HR) for hip fracture was still highest in the PU+GFR+ group. However, the PU+GFR− group had a higher HR for hip fracture than the PU−GFR+ group (PU+GFR+ : HR, 1.69; 95% confidence interval [CI], 1.57 to 1.81; PU+GFR− : HR, 1.37; 95% CI, 1.30 to 1.46; PU−GFR+ : HR, 1.20; 95% CI, 1.16 to 1.24 using the PU−GFR− group as the reference category).
Conclusion The present study demonstrated that DKD was significantly associated with a higher risk of hip fracture, with proteinuria as a major determinant.
Citations
Citations to this article as recorded by
Proteinuria screening and risk of bone fracture: a retrospective cohort study using a nationwide population-based database Akira Okada, Akira Honda, Hideaki Watanabe, Yusuke Sasabuchi, Shotaro Aso, Kayo Ikeda Kurakawa, Masaomi Nangaku, Toshimasa Yamauchi, Hideo Yasunaga, Hirotaka Chikuda, Takashi Kadowaki, Satoko Yamaguchi Clinical Kidney Journal.2024;[Epub] CrossRef
Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong David Tak Wai Lui, Tingting Wu, Eric Ho Man Tang, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong Diabetes Research and Clinical Practice.2023; 197: 110576. CrossRef
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023) Christian Muschitz, Alexandra Kautzky-Willer, Yvonne Winhofer, Martina Rauner, Judith Haschka, Daniel Cejka, Robert Wakolbinger-Habel, Peter Pietschmann Wiener klinische Wochenschrift.2023; 135(S1): 207. CrossRef
Association between exercise and risk of fractures in new-onset type 2 diabetes: a retrospective cohort study Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Kyoung-Ah Kim, Kyungdo Han, Han Seok Choi Archives of Osteoporosis.2023;[Epub] CrossRef
Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim Diabetes & Metabolism Journal.2023; 47(4): 523. CrossRef
Background We aim to validate the diagnostic performance of thyroid core needle biopsy (CNB) for diagnosing malignancy in clinical settings to align with the changes made in recently updated thyroid CNB guidelines.
Methods We retrospectively analyzed 1,381 thyroid CNB and 2,223 fine needle aspiration (FNA) samples. The FNA and CNB slides were interpreted according to the Bethesda System for Reporting Thyroid Cytopathology and updated practice guidelines for thyroid CNB, respectively.
Results Compared to FNA, CNB showed lower rates of inconclusive results: categories I (2.8% vs. 11.2%) and III (1.2% vs. 6.2%), and higher rates of categories II (60.9% vs. 50.4%) and IV (17.5% vs. 2.0%). The upper and lower bounds of the risk of malignancy (ROM) for category IV of CNB were 43.2% and 26.6%, respectively. The CNB subcategory IVb with nuclear atypia had a higher ROM than the subcategory without nuclear atypia (40%–62% vs. 23%–36%). In histologically confirmed cases, there was no significant difference in the diagnostic performance between CNB and FNA for malignancy. However, neoplastic diseases were more frequently detected by CNB than by FNA (88.8% vs. 77.6%, P=0.046). In category IV, there was no difference in unnecessary surgery rate between CNB and FNA (4.7% vs. 6.9%, P=0.6361).
Conclusion Thyroid CNB decreased the rate of inconclusive results and showed a higher category IV diagnostic rate than FNA. The revised guidelines for thyroid CNB proved to be an excellent reporting system for assessing thyroid nodules.
Citations
Citations to this article as recorded by
Examining the impact of several factors including COVID‐19 on thyroid fine‐needle aspiration biopsy Muzaffer Serdar Deniz, Merve Dindar Diagnostic Cytopathology.2024; 52(1): 42. CrossRef
Consensus SFE-AFCE-SFMN 2022 sur la prise en charge des nodules thyroïdiens : intérêt et place de la cytologie thyroïdienne Myriam Decaussin-Petrucci, Beatrix Cochand Priollet, Emannuelle Leteurtre, Frédérique Albarel, Françoise Borson-Chazot Annales de Pathologie.2024; 44(1): 20. CrossRef
A comparative analysis of core needle biopsy and repeat fine needle aspiration in patients with inconclusive initial cytology of thyroid nodules Xuejiao Su, Can Yue, Wanting Yang, Buyun Ma Frontiers in Endocrinology.2024;[Epub] CrossRef
The Diagnostic Role of Repeated Biopsy of Thyroid Nodules with Atypia of Undetermined Significance with Architectural Atypia on Core-Needle Biopsy Hye Hyeon Moon, Sae Rom Chung, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee, Jung Hwan Baek Endocrinology and Metabolism.2024; 39(2): 300. CrossRef
Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024 Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung, International Journal of Thyroidology.2024; 17(1): 208. CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 2. Surgical Management of Thyroid Cancer 2024 Yoon Young Cho, Cho Rok Lee, Ho-Cheol Kang, Bon Seok Koo, Hyungju Kwon, Sun Wook Kim, Won Woong Kim, Jung-Han Kim, Dong Gyu Na, Young Joo Park, Kyorim Back, Young Shin Song, Seung Hoon Woo, Ho-Ryun Won, Chang Hwan Ryu, Jee Hee Yoon, Min Kyoung Lee, Eun Ky International Journal of Thyroidology.2024; 17(1): 30. CrossRef
Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis Chao Qin, Sijia Cai, Yanyu Qi, Meilin Liu, Weibo Xu, Min Yin, Haitao Tang, Qinghai Ji, Tian Liao, Yu Wang Frontiers in Endocrinology.2024;[Epub] CrossRef
Current role of interventional radiology in thyroid nodules Onur Taydas, Erbil Arik, Omer Faruk Sevinc, Ahmet Burak Kara, Mustafa Ozdemir, Hasret Cengiz, Zulfu Bayhan, Mehmet Halil Ozturk Frontiers in Endocrinology.2024;[Epub] CrossRef
A simplified four-tier classification for thyroid core needle biopsy M. Paja, J. L. Del Cura, R. Zabala, I. Korta, Mª T. Gutiérrez, A. Expósito, A. Ugalde Journal of Endocrinological Investigation.2024;[Epub] CrossRef
Cytology fine-needle aspiration and surgical pathology core needle biopsy reporting: blurred lines or battle lines? Paul A. VanderLaan Journal of the American Society of Cytopathology.2024;[Epub] CrossRef
Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry Meejeong Kim, Sora Jeon, Chan Kwon Jung Endocrine Pathology.2023; 34(2): 247. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy Chan Kwon Jung Journal of Pathology and Translational Medicine.2023; 57(4): 208. CrossRef
A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model Faridul Haq, Andrey Bychkov, Chan Kwon Jung Endocrine Pathology.2022; 33(4): 472. CrossRef